Veeva Q2 revenue, adjusted net income beats estimates

Veeva Systems

27/08/2025 21:18

Overview

Veeva fiscal Q2 2026 rev rises 17% yr/yr to $789.1 mln, beating analyst expectations, per LSEG data

Adjusted net income for fiscal Q2 beats analyst estimates, per LSEG data

Co highlights advancements in AI initiatives and strategic partnerships

Outlook

Veeva sees Q3 revenue between $790 mln and $793 mln

Company expects Q3 non-GAAP EPS between $1.94 and $1.95

Veeva projects FY revenue between $3.134 bln and $3.140 bln

Company anticipates FY non-GAAP EPS of approximately $7.78

Result Drivers

AI INITIATIVES - Veeva AI and Veeva Data Cloud are enabling transformational change for life sciences, per CEO Peter Gassner

VAULT CRM MILESTONES - Two top 20 biopharmas went live with Vault CRM, now with over 100 customers, expanding capabilities

STRATEGIC PARTNERSHIP - Veeva and IQVIA's partnership allows joint customers to use products and services efficiently across commercial and clinical

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$789.08 mln
$768.40 mln (25 Analysts)
Q2 EPS
$1.19
Q2 Adjusted Net Income
Beat
$333.40 mln
$316.40 mln (22 Analysts)
Q2 Net Income
$200.31 mln
Q2 Adjusted Operating Income
Beat
$352.60 mln
$337.90 mln (24 Analysts)
Q2 Pretax Profit
$265.36 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 11 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Veeva Systems Inc is $300.00, about 4.5% above its August 26 closing price of $286.54

The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 31 three months ago

Press Release: ID:nPn7Nsp6Ka

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)